Journal article

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial

Maria Pearse, Carol Fraser-Browne, Ian D Davis, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Annette Haworth, Chakiath Jose, David J Joseph, Tee S Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel A Spry, Colin I Tang, Sandra Turner, Scott G Williams, Kirsty Wiltshire, Henry H Woo, Andrew Kneebone



OBJECTIVES: To test the hypothesis that observation with early salvage radiotherapy (SRT) is not inferior to 'standard' treatment with adjuvant RT (ART) with respect to biochemical failure in patients with pT3 disease and/or positive surgical margins (SMs) after radical prostatectomy (RP). To compare the following secondary endpoints between the two arms: patient-reported outcomes, adverse events, biochemical failure-free survival, overall survival, disease-specific survival, time to distant failure, time to local failure, cost utility analysis, quality adjusted life years and time to androgen deprivation. PATIENTS AND METHODS: The Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial i..

View full abstract